The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 6 rounds in the feed, most often at Series A and in Biotech.
We provide early-stage capital to the next generation of awesome life science entrepreneurs and the platform where they can realize their visions.
Venture capitalSan Francisco, CA, USAmissionbiocapital.comRounds from 2021-06-23 to 2026-11-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Oyster Therapeutics A pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven diseases like Alzheimer’s | Series A Verified against 4 of 21 sources | $60M | 2026-11-10 | [ PART ] |
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Funding round |
| $350M |
| 2026-10-28 |
| [ PART ] |
Breye Therapeutics A clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases | Series A Verified against 4 of 11 sources | $75.8M | 2026-09-29 | [ LEAD ] |
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65M | 2022-06-14 | [ PART ] |
Tune Therapeutics TuneTx sells genetic tuning technology aimed at transforming health through gene and regenerative therapies, targeting diseases at their source. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2021-12-02 | [ PART ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2021-06-23 | [ PART ] |